Category: Parkinson's Disease: Non-Motor Symptoms
Objective: The aim of the present study was to analyze the progression of non-motor symptoms (NMS) in PD patients from a Spanish cohort and to compare with a control group [1,2].
Background: Non-motor symptoms (NMS) are frequent and disabling in Parkinson´s disease (PD) patients and progress throughout the course of the disease.
Method: PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed-up during 2 years. NMS assessment was conducted at baseline (V0) and at 24 months ± 1 month (V2) and included: Non-Motor Symptoms Scale (NMSS); Parkinson’s Disease Sleep Scale (PDSS); Visual Analog Scale-Pain (VAS-Pain); Visual Analog Fatigue Scale (VAFS); Parkinson’s Disease Cognitive Rating Scale (PD-CRS); Beck Depression Inventory-II (BDI-II); Neuropsychiatric Inventory (NPI); Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease-Rating Scale (QUIP-RS). Wilconxon´s rank sum test was performed for testing the changes from baseline.
Results: Mean NMS burden (NMSS total score) was significantly increased in PD patients by 18.8% (from 45.1 ± 37.6 to 53.6 ± 42.3; p<0.0001; N=501) compared to no change observed in controls (from 14.7 ± 18.7 to 14.7 ± 21.8; p=0.428; N=122) (p=0.007). Specifically, the mean score of all domains of the NMSS increased significantly from V0 to V2 (p<0.001). However, in 201 patients (40.1%) a score at V2 equal to or less than the baseline NMSS total score was observed. In PD group it was also observed a significant change in the score of the PD-CRS (from 92.0 ± 15.7 to 90.3 ± 18.1; p<0.0001; N=500), VAS-Pain (from 2.6 ± 2.9 to 2.9 ± 2.9; p=0.013; N=501) and VAFS-Physical (from 2.8 ± 2.7 to 3.2 ± 2.8; p=0.010; N=501), but in none scale in controls.
Conclusion: NMS burden, as a whole, progressed after 2 years follow-up in PD patients from the COPPADIS cohort. In practice, more than half of PD patients will present a NMS burden worsening at 2 years and it is necessary to ask about NMS.
References: 1. Santos-García D, Mir P, Cubo E, et al.; COPPADIS Study Group. BMC Neurol 2016;16:26. 2. Santos García D, Jesús S, Aguilar M, et al.; COPPADIS Study Group. Eur J Neurol 2019;16:1399-407.
To cite this abstract in AMA style:
C. Cores Bartolomé, D. García, T. Fonticoba, C. Miró, E. Castro, JM. Gonzalez, S. Maestre, M. Aguilar, P. Pastor, L. Planellas Giné, M. Cosgaya, J. Garcia Caldentey, N. Caballol Pons, I. Legarda Ramirez, J. Hernandez Vara, I. Cabo, L. Lopez Manzanares, I. Gonzalez Aramburu, MA. Avila, MJ. Catalan Alonso, V. Nogueira, V. Puente, JM. Garcia Moreno, C. Borrue Fernandez, B. Solano Vila, M. Alvarez Sauco, L. Vela Desojo, S. Escalante, E. Cubo, F. Carrillo Padilla, JC. Martinez Castrillo, P. Sanchez Alonso, MG. Alonso Losada, N. Lopez Ariztegui, I. Gaston Zubimendi, J. Kulisevsky, M. Blazquez Estrada, M. Seijo Martinez, J. Ruiz Martinez, C. Valero Merino, M. Kurtis, O. de Fábregues-Boixer, J. Gonzalez Ardura, CM. Ordas Bandera, L. Lopez Diaz, P. Mir Rivera, P. Martinez Martin. Non-Motor Symptoms Progression After 2 years Follow-up in Parkinson´s Disease. Results from the COPPADIS Cohort and Comparison with a Control Group [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/non-motor-symptoms-progression-after-2-years-follow-up-in-parkinsons-disease-results-from-the-coppadis-cohort-and-comparison-with-a-control-group/. Accessed June 15, 2025.« Back to MDS Virtual Congress 2021
MDS Abstracts - https://www.mdsabstracts.org/abstract/non-motor-symptoms-progression-after-2-years-follow-up-in-parkinsons-disease-results-from-the-coppadis-cohort-and-comparison-with-a-control-group/